415 related articles for article (PubMed ID: 35762829)
1. Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease.
Tanner JA; Iaccarino L; Edwards L; Asken BM; Gorno-Tempini ML; Kramer JH; Pham J; Perry DC; Possin K; Malpetti M; Mellinger T; Miller BL; Miller Z; Mundada NS; Rosen HJ; Soleimani-Meigooni DN; Strom A; La Joie R; Rabinovici GD
Brain; 2022 Dec; 145(12):4489-4505. PubMed ID: 35762829
[TBL] [Abstract][Full Text] [Related]
2. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
[TBL] [Abstract][Full Text] [Related]
3. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
[TBL] [Abstract][Full Text] [Related]
4. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.
Strom A; Iaccarino L; Edwards L; Lesman-Segev OH; Soleimani-Meigooni DN; Pham J; Baker SL; Landau SM; Jagust WJ; Miller BL; Rosen HJ; Gorno-Tempini ML; Rabinovici GD; La Joie R;
Brain; 2022 Apr; 145(2):713-728. PubMed ID: 34373896
[TBL] [Abstract][Full Text] [Related]
5. Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET.
Devous MD; Fleisher AS; Pontecorvo MJ; Lu M; Siderowf A; Navitsky M; Kennedy I; Southekal S; Harris TS; Mintun MA
J Alzheimers Dis; 2021; 80(3):1091-1104. PubMed ID: 33682705
[TBL] [Abstract][Full Text] [Related]
6. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
[TBL] [Abstract][Full Text] [Related]
7. Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer's disease.
Visser D; Verfaillie SCJ; Wolters EE; Coomans EM; Timmers T; Tuncel H; Boellaard R; Golla SSV; Windhorst AD; Scheltens P; van der Flier WM; van Berckel BNM; Ossenkoppele R
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1951-1963. PubMed ID: 34997294
[TBL] [Abstract][Full Text] [Related]
8. Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
Cody KA; Langhough RE; Zammit MD; Clark L; Chin N; Christian BT; Betthauser TJ; Johnson SC
Brain; 2024 Jun; 147(6):2144-2157. PubMed ID: 38667631
[TBL] [Abstract][Full Text] [Related]
9. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
Pontecorvo MJ; Devous MD; Kennedy I; Navitsky M; Lu M; Galante N; Salloway S; Doraiswamy PM; Southekal S; Arora AK; McGeehan A; Lim NC; Xiong H; Truocchio SP; Joshi AD; Shcherbinin S; Teske B; Fleisher AS; Mintun MA
Brain; 2019 Jun; 142(6):1723-1735. PubMed ID: 31009046
[TBL] [Abstract][Full Text] [Related]
10. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden.
Rabinovici GD; Furst AJ; Alkalay A; Racine CA; O'Neil JP; Janabi M; Baker SL; Agarwal N; Bonasera SJ; Mormino EC; Weiner MW; Gorno-Tempini ML; Rosen HJ; Miller BL; Jagust WJ
Brain; 2010 Feb; 133(Pt 2):512-28. PubMed ID: 20080878
[TBL] [Abstract][Full Text] [Related]
11. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
12. Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer's disease.
Visser D; Wolters EE; Verfaillie SCJ; Coomans EM; Timmers T; Tuncel H; Reimand J; Boellaard R; Windhorst AD; Scheltens P; van der Flier WM; Ossenkoppele R; van Berckel BNM
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3165-3175. PubMed ID: 32462397
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis.
Botha H; Mantyh WG; Murray ME; Knopman DS; Przybelski SA; Wiste HJ; Graff-Radford J; Josephs KA; Schwarz CG; Kremers WK; Boeve BF; Petersen RC; Machulda MM; Parisi JE; Dickson DW; Lowe V; Jack CR; Jones DT
Brain; 2018 Apr; 141(4):1201-1217. PubMed ID: 29538658
[TBL] [Abstract][Full Text] [Related]
14. Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
Gordon BA; Blazey TM; Christensen J; Dincer A; Flores S; Keefe S; Chen C; Su Y; McDade EM; Wang G; Li Y; Hassenstab J; Aschenbrenner A; Hornbeck R; Jack CR; Ances BM; Berman SB; Brosch JR; Galasko D; Gauthier S; Lah JJ; Masellis M; van Dyck CH; Mintun MA; Klein G; Ristic S; Cairns NJ; Marcus DS; Xiong C; Holtzman DM; Raichle ME; Morris JC; Bateman RJ; Benzinger TLS
Brain; 2019 Apr; 142(4):1063-1076. PubMed ID: 30753379
[TBL] [Abstract][Full Text] [Related]
15. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
[TBL] [Abstract][Full Text] [Related]
16. Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease.
Biel D; Luan Y; Brendel M; Hager P; Dewenter A; Moscoso A; Otero Svaldi D; Higgins IA; Pontecorvo M; Römer S; Steward A; Rubinski A; Zheng L; Schöll M; Shcherbinin S; Ewers M; Franzmeier N;
Alzheimers Res Ther; 2022 Nov; 14(1):166. PubMed ID: 36345046
[TBL] [Abstract][Full Text] [Related]
17. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
[TBL] [Abstract][Full Text] [Related]
18. Asymmetries of amyloid-β burden and neuronal dysfunction are positively correlated in Alzheimer's disease.
Frings L; Hellwig S; Spehl TS; Bormann T; Buchert R; Vach W; Minkova L; Heimbach B; Klöppel S; Meyer PT
Brain; 2015 Oct; 138(Pt 10):3089-99. PubMed ID: 26280595
[TBL] [Abstract][Full Text] [Related]
19. Regional [
Wolters EE; Ossenkoppele R; Verfaillie SCJ; Coomans EM; Timmers T; Visser D; Tuncel H; Golla SSV; Windhorst AD; Boellaard R; van der Flier WM; Teunissen CE; Scheltens P; van Berckel BNM
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2866-2878. PubMed ID: 32291510
[TBL] [Abstract][Full Text] [Related]
20. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease.
Lehmann M; Ghosh PM; Madison C; Laforce R; Corbetta-Rastelli C; Weiner MW; Greicius MD; Seeley WW; Gorno-Tempini ML; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2013 Mar; 136(Pt 3):844-58. PubMed ID: 23358601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
